Evoke holds a significant market position as the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults. The company expanded access through partnerships with Omnicell and Brentwood Pharmacy while securing patent protection extending market exclusivity to November 2038. Despite strong product growth, the company faced profitability challenges with operating losses offset by growing top-line momentum.
Cyborg Score Rationale
While GIMOTI demonstrated strong commercial traction with 60%+ YoY growth and extended patent exclusivity, the company faced persistent operating losses and limited scale before acquisition. The acquisition by QOL Medical at a substantial premium reflected strategic value but signaled challenges in independent viability.
Top Insights
GIMOTI achieved 61% YoY revenue growth in Q3 2025 with $4.3M in net product sales
Exclusive patent protection extended to November 2038 provides substantial competitive moat
Expanded distribution partnerships with Omnicell and Brentwood Pharmacy increased market access
Acquired by QOL Medical in December 2025 for $11.00/share, representing 139.7% premium to pre-announcement price